Henlius’ HLX04-O (biosimilar, bevacizumab) Receives the US FDA’s IND Approval for wAMD

 Henlius’ HLX04-O (biosimilar, bevacizumab) Receives the US FDA’s IND Approval for wAMD

Henlius Receives the NMPA’s Approval for HLX03 (biosimilar, adalimumab) to Treat Autoimmune Disease

Shots:

  • The US FDA has approved the IND application of HLX04-O for the treatment of wAMD
  • The P-III clinical study of HLX04-O will be conducted to further evaluate the efficacy and safety of HLX04-O in patients with wAMD in the near future. The study will enroll 388 patients from Chinese mainand, Australia, Russian Federation, Singapore, Spain and Poland
  • Henlius and Essex will speed up the global clinical trials of HLX04-O and apply approval in different countries and regions across the globe based on the research results

Click here to­ read full press release/ article | Ref: Henlius | Image: Henlius

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post